Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TNF therapy and body composition in early rheumatoid arthritis
ISRCTN39045408Phase 4Completed
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in rheumatoid arthritis (RA) comparing Methotrexate + sulfasalazine + hydroxychloroquine with Methotrexate + infliximab (2 arms). Primary endpoint: Body composition and bone mineral density changes at 24 months. Started Mar 2004; status: completed.
02
Drugs
infliximabmethotrexate5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN39045408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39045408.